{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:04:25Z","timestamp":1793826265039,"version":"4.6.1"},"reference-count":116,"publisher":"European Respiratory Society (ERS)","issue":"179","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2025,12,11]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Elexacaftor\u2013tezacaftor\u2013ivacaftor (ETI) is a highly effective modulator therapy associated with significant improvements in respiratory function and quality of life among people living with cystic fibrosis (CF). However, ETI has also been shown to result in significant weight gain and there is emerging interest regarding traditional cardiometabolic risk factors. This systematic review investigated the effects of ETI on cardiometabolic risk factors (obesity\/overweight, body composition, glucose metabolism, lipids, blood pressure and bone parameters) in people living with CF. This review adhered with Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and was registered in PROSPERO (CRD42025630118). The following databases were searched in December 2024 and June 2025: PubMed, Scopus, Web of Science and Embase. A total of 54 publications met inclusion criteria (including ETI treatment duration &gt;4\u2005months, &gt;10\u2005total participants, empirical studies) and underwent data extraction. Risk of bias was assessed using National Institutes of Health tools. Results were prepared in tabular format and narrative summary. There was notable heterogeneity in study design and results. In published studies to date, ETI initiation was generally followed by a decrease in glycated haemoglobin, but minimal change in other glycaemic or insulinaemic parameters. Some studies reported increased blood pressure, hypertension and overweight\/obesity classification, and cholesterol levels. The observational design and short duration of most studies limit the ability to conclude direct effects of ETI, particularly in the long term. However, we conclude there is likely increased risk of certain traditional cardiometabolic risk factors in ageing people with CF, thus highlighting the importance of clinical surveillance and prompt intervention if needed.<\/jats:p>","DOI":"10.1183\/16000617.0197-2025","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:30:15Z","timestamp":1772011815000},"page":"250197","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of elexacaftor\u2013tezacaftor\u2013ivacaftor on cardiometabolic risk factors: a systematic review"],"prefix":"10.1183","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1364-7855","authenticated-orcid":false,"given":"Heather","family":"Girouard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Jaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-699X","authenticated-orcid":false,"given":"Laure","family":"Alexandre-Heymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad\u00e8le","family":"Coriati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026033102052386000_35.179.250197.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.01.009"},{"key":"2026033102052386000_35.179.250197.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2014.04.001"},{"key":"2026033102052386000_35.179.250197.3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Animal Model Exp Med"},{"key":"2026033102052386000_35.179.250197.4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009746"},{"key":"2026033102052386000_35.179.250197.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586"},{"key":"2026033102052386000_35.179.250197.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2019.08.016"},{"key":"2026033102052386000_35.179.250197.7","unstructured":"Cystic Fibrosis Canada . 2023 annual data report. Date last updated: December 2024. Date last accessed: 26 October 2025. https:\/\/cystic-fibrosis.cdn.prismic.io\/cystic-fibrosis\/Z9sI9jiBA97GirFZ_2023-Annual-Data-ReportWEB-2-.pdf"},{"key":"2026033102052386000_35.179.250197.8","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26954"},{"key":"2026033102052386000_35.179.250197.9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2026033102052386000_35.179.250197.10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026033102052386000_35.179.250197.11","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-25.3.192"},{"key":"2026033102052386000_35.179.250197.12","first-page":"100286","article-title":"The role of modulators in cystic fibrosis related diabetes","volume":"27","author":"Merjaneh","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jada.2008.02.020"},{"key":"2026033102052386000_35.179.250197.14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin Nutr"},{"key":"2026033102052386000_35.179.250197.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.03.004"},{"key":"2026033102052386000_35.179.250197.16","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin Nutr"},{"key":"2026033102052386000_35.179.250197.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"key":"2026033102052386000_35.179.250197.18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s41182-019-0165-6","article-title":"A step by step guide for conducting a systematic review and meta-analysis with simulation data","volume":"47","author":"Tawfik","year":"2019","journal-title":"Trop Med Health"},{"key":"2026033102052386000_35.179.250197.19","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-0897-3"},{"key":"2026033102052386000_35.179.250197.20","first-page":"7","article-title":"Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better?","volume":"7","author":"Ma","year":"2020","journal-title":"Mil Med Res"},{"key":"2026033102052386000_35.179.250197.21","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2017-110668"},{"key":"2026033102052386000_35.179.250197.22","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"2026033102052386000_35.179.250197.23","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/nu16183103","article-title":"Is obesity a problem in new cystic fibrosis treatments?","volume":"16","author":"Solis-Garcia","year":"2024","journal-title":"Nutrients"},{"key":"2026033102052386000_35.179.250197.24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.jcf.2023.06.010","article-title":"Body mass index and nutritional intake following elexacaftor\/tezacaftor\/ivacaftor modulator therapy in adults with cystic fibrosis","volume":"22","author":"Caley","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcf.2023.06.002","article-title":"Weight a minute: exploring the effect on weight and body composition after the initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with CF","volume":"22","author":"Proud","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir Res"},{"key":"2026033102052386000_35.179.250197.27","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1210\/clinem\/dgaf099","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on glucose tolerance in adolescents with cystic fibrosis","volume":"110","author":"Galderisi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033102052386000_35.179.250197.28","doi-asserted-by":"crossref","first-page":"114176","DOI":"10.1016\/j.jpeds.2024.114176","article-title":"Reported adverse events in a multicenter cohort of patients ages 6\u201318 years with cystic fibrosis and at least one F508del allele receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"274","author":"Terlizzi","year":"2024","journal-title":"J Pediatr"},{"key":"2026033102052386000_35.179.250197.29","doi-asserted-by":"crossref","first-page":"e27463","DOI":"10.1002\/ppul.27463","article-title":"Growth, body composition, and strength of children with cystic fibrosis treated with elexacaftor\/tezacaftor\/ivacaftor (ETI)","volume":"60","author":"Boat","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.30","doi-asserted-by":"crossref","first-page":"e71044","DOI":"10.1002\/ppul.71044","article-title":"Peripheral muscle function and body composition in people with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor: a cross-sectional single-centre study","volume":"60","author":"Clayton","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jcf.2025.02.001","article-title":"Cardiovascular function in people with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor: a cross-sectional, observational, single-centre study","volume":"24","author":"Clayton","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.32","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/jcm11041021","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"2026033102052386000_35.179.250197.33","doi-asserted-by":"crossref","first-page":"106646","DOI":"10.1016\/j.rmed.2021.106646","article-title":"Effectiveness and safety of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del\/minimal function genotype","volume":"189","author":"Carnovale","year":"2021","journal-title":"Respir Med"},{"key":"2026033102052386000_35.179.250197.34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5457\/p2005-114.354","article-title":"Assessment of physical condition in cystic fibrosis patients during 12-month treatment with cystic fibrosis transmembrane conductance regulator modulators","volume":"20","author":"Hrvoi\u0107","year":"2024","journal-title":"Central Eur J Paed"},{"key":"2026033102052386000_35.179.250197.35","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.26318"},{"key":"2026033102052386000_35.179.250197.36","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.pupt.2024.102328","article-title":"Elexacaftor\/tezacaftor\/ivacaftor, a game-changer in cystic fibrosis: the Portuguese experience","volume":"87","author":"Fragoso","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"key":"2026033102052386000_35.179.250197.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.09.001"},{"key":"2026033102052386000_35.179.250197.38","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"2026033102052386000_35.179.250197.39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcf.2024.11.009","article-title":"Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"24","author":"Gramegna","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.40","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor\u2013tezacaftor\u2013ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026033102052386000_35.179.250197.41","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026033102052386000_35.179.250197.42","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.3390\/nu16193293","article-title":"Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor therapy on body composition, dietary intake, biomarkers, and quality of life in people with cystic fibrosis: a prospective observational study","volume":"16","author":"Hevilla","year":"2024","journal-title":"Nutrients"},{"key":"2026033102052386000_35.179.250197.43","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor\u2013tezacaftor\u2013ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.clnu.2025.04.027","article-title":"Dietary intake remains unchanged while nutritional status improves in children and adults with cystic fibrosis on elexacaftor\/tezacaftor\/ivacaftor","volume":"50","author":"Enaud","year":"2025","journal-title":"Clin Nutr"},{"key":"2026033102052386000_35.179.250197.45","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.clnesp.2025.04.006","article-title":"Assessment of dietary intake in adults with cystic fibrosis pre and post commencement of elexacaftor\/tezacaftor\/ivacaftor","volume":"67","author":"Loel","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"2026033102052386000_35.179.250197.46","first-page":"100272","article-title":"Body composition in individuals with cystic fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.47","doi-asserted-by":"crossref","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes","volume":"49","author":"Grancini","year":"2023","journal-title":"Diabetes Metab"},{"key":"2026033102052386000_35.179.250197.48","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","article-title":"A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation","volume":"42","author":"Knott-Torcal","year":"2023","journal-title":"Clin Nutr"},{"key":"2026033102052386000_35.179.250197.49","doi-asserted-by":"crossref","first-page":"1477674","DOI":"10.3389\/fnut.2024.1477674","article-title":"Increased fat mass and obesity risk after elexacaftor\u2013tezacaftor\u2013ivacaftor therapy in young adults with cystic fibrosis","volume":"11","author":"Merino Sanchez-Canete","year":"2024","journal-title":"Front Nutr"},{"key":"2026033102052386000_35.179.250197.50","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/ppul.27272","article-title":"Effects on growth, weight and body composition after CFTR modulators in children with cystic fibrosis","volume":"59","author":"Lopez Cardenes","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcf.2024.09.022","article-title":"Development of metabolic syndrome in people with cystic fibrosis one year after exposure to elexacaftor\u2013tezacaftor\u2013ivacaftor","volume":"24","author":"Ratti","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.52","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1038\/s41598-024-59622-2","article-title":"Elexacaftor\/tezacaftor\/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis","volume":"14","author":"Westholter","year":"2024","journal-title":"Sci Rep"},{"key":"2026033102052386000_35.179.250197.53","doi-asserted-by":"crossref","first-page":"112425","DOI":"10.1016\/j.nut.2024.112425","article-title":"Impact of CFTR modulator therapy on body composition as assessed by thoracic computed tomography: a follow-up study","volume":"123","author":"Navas-Moreno","year":"2024","journal-title":"Nutrition"},{"key":"2026033102052386000_35.179.250197.54","doi-asserted-by":"crossref","first-page":"e28508","DOI":"10.1016\/j.heliyon.2024.e28508","article-title":"Real-world effectiveness of elexacaftor\/tezacaftor\/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis","volume":"10","author":"Keens","year":"2024","journal-title":"Heliyon"},{"key":"2026033102052386000_35.179.250197.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.11.005"},{"key":"2026033102052386000_35.179.250197.56","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.57","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.58","doi-asserted-by":"crossref","first-page":"111839","DOI":"10.1016\/j.diabres.2024.111839","article-title":"Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice","volume":"216","author":"Aguilera Garcia","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026033102052386000_35.179.250197.59","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/clinem\/dgae857","article-title":"Glycemia and insulin secretion in cystic fibrosis two years after elexacaftor\/tezacaftor\/ivacaftor: PROMISE-ENDO","volume":"110","author":"Chan","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033102052386000_35.179.250197.60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/clinem\/dgad443","article-title":"Preservation of \u03b2-cell function in pancreatic insufficient cystic fibrosis with highly effective CFTR modulator therapy","volume":"109","author":"Flatt","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033102052386000_35.179.250197.61","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/jcm11144149","article-title":"Impact of CFTR modulators on beta-cell function in children and young adults with cystic fibrosis","volume":"11","author":"Piona","year":"2022","journal-title":"J Clin Med"},{"key":"2026033102052386000_35.179.250197.62","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/life14101309","article-title":"One-year effect of elexacaftor\/tezacaftor\/ivacaftor therapy on HbA1c levels and insulin requirement in patients with insulin-dependent cystic fibrosis-related diabetes: a retrospective observational study","volume":"14","author":"Bassi","year":"2024","journal-title":"Life"},{"key":"2026033102052386000_35.179.250197.63","first-page":"100311","article-title":"Glycemia and \u03b2-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis","volume":"30","author":"Chan","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jcf.2025.03.007","article-title":"Hemoglobin A1c in youth and adults with cystic fibrosis related diabetes decreases after elexacaftor\u2013tezacaftor\u2013ivacaftor","volume":"24","author":"Wood","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.65","first-page":"100307","article-title":"CGM patterns in adults with cystic fibrosis-related diabetes before and after elexacaftor\u2013tezacaftor\u2013ivacaftor therapy","volume":"30","author":"Crow","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.66","first-page":"100332","article-title":"The changing landscape of treatment for cystic fibrosis related diabetes","volume":"35","author":"Amini","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.67","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clnesp.2023.08.028","article-title":"Effect of 18 months elexacaftor\u2013tezacaftor\u2013ivacaftor on body mass index and glycemic control in adults with cystic fibrosis","volume":"58","author":"Taelman","year":"2023","journal-title":"Clin Nutr ESPEN"},{"key":"2026033102052386000_35.179.250197.68","doi-asserted-by":"crossref","first-page":"107882","DOI":"10.1016\/j.rmed.2024.107882","article-title":"Real-world impact of elexacaftor\u2013tezacaftor\u2013ivacaftor treatment in young people with cystic fibrosis: a longitudinal study","volume":"236","author":"Connett","year":"2025","journal-title":"Respir Med"},{"key":"2026033102052386000_35.179.250197.69","doi-asserted-by":"crossref","first-page":"1327958","DOI":"10.3389\/fmolb.2023.1327958","article-title":"One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes","volume":"10","author":"Castaldo","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026033102052386000_35.179.250197.70","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jcf.2025.04.012","article-title":"LONGITUDE: an observational study of the long-term effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people aged \u226512 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry \u2013 2-year analysis","volume":"24","author":"Vega-Hernandez","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2023.03.002"},{"key":"2026033102052386000_35.179.250197.72","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01771.x"},{"key":"2026033102052386000_35.179.250197.73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor\u2013tezacaftor\u2013ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2026033102052386000_35.179.250197.74","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.75","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jcf.2023.07.001","article-title":"Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy","volume":"22","author":"Yuzyuk","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.76","first-page":"100391","article-title":"Cholesterol and triglyceride concentrations following 12\u201318 months of clinically prescribed elexacaftor\u2013tezacaftor\u2013ivacaftor \u2013 PROMISE sub-study","volume":"40","author":"Bass","year":"2025","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.77","first-page":"101102","article-title":"Effect of elexacaftor\u2013tezacaftor\u2013ivacaftor on lipid parameters in adults with cystic fibrosis: a single centre preliminary report","volume":"86","author":"Docherty","year":"2024","journal-title":"Respir Med and Res"},{"key":"2026033102052386000_35.179.250197.78","doi-asserted-by":"crossref","first-page":"17422","DOI":"10.1038\/s41598-024-68511-7","article-title":"Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del\/CFTR variant genotype after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"14","author":"Castaldo","year":"2024","journal-title":"Sci Rep"},{"key":"2026033102052386000_35.179.250197.79","doi-asserted-by":"crossref","first-page":"13178","DOI":"10.1038\/s41598-024-63904-0","article-title":"Subclinical vascular, hemodynamic and arterial stiffness changes in adults with cystic fibrosis: cross-sectional observational study","volume":"14","author":"Pessoa","year":"2024","journal-title":"Sci Rep"},{"key":"2026033102052386000_35.179.250197.80","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/01.HYP.0000145901.81989.46","article-title":"Blood pressure and the cystic fibrosis gene: evidence for lower pressure rises with age in female carriers","volume":"44","author":"Super","year":"2004","journal-title":"Hypertension"},{"key":"2026033102052386000_35.179.250197.81","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026033102052386000_35.179.250197.82","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026033102052386000_35.179.250197.83","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0392OC"},{"key":"2026033102052386000_35.179.250197.84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02435-2024"},{"key":"2026033102052386000_35.179.250197.85","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0021OC"},{"key":"2026033102052386000_35.179.250197.86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2026033102052386000_35.179.250197.87","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022"},{"key":"2026033102052386000_35.179.250197.88","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1164\/rccm.202411-2231OC","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in adults and adolescents with cystic fibrosis and at least one F508del allele: a phase 3, open-label extension study","volume":"211","author":"Daines","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026033102052386000_35.179.250197.89","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"2026033102052386000_35.179.250197.90","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70100-3"},{"key":"2026033102052386000_35.179.250197.91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.04.016"},{"key":"2026033102052386000_35.179.250197.92","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00355-1"},{"key":"2026033102052386000_35.179.250197.93","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2015.10.012"},{"key":"2026033102052386000_35.179.250197.94","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fped.2014.00033","article-title":"Body composition and pulmonary function in cystic fibrosis","volume":"2","author":"Sheikh","year":"2014","journal-title":"Front Pediatr"},{"key":"2026033102052386000_35.179.250197.95","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ppul.26243","article-title":"Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study","volume":"58","author":"Gur","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.96","doi-asserted-by":"crossref","first-page":"e71280","DOI":"10.1002\/ppul.71280","article-title":"Elexacaftor\/tezacaftor\/ivacaftor effect on bone density and body composition: a retrospective analysis","volume":"60","author":"Trost","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.97","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24925"},{"key":"2026033102052386000_35.179.250197.98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcjd.2024.09.001","article-title":"Cystic fibrosis-related diabetes: a first Canadian clinical practice guideline","volume":"49","author":"Coriati","year":"2025","journal-title":"Can J Diabetes"},{"key":"2026033102052386000_35.179.250197.99","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jcf.2021.05.010","article-title":"HOMA indices as screening tests for cystic fibrosis-related diabetes","volume":"21","author":"Toin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.100","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"2026033102052386000_35.179.250197.101","doi-asserted-by":"crossref","first-page":"e71156","DOI":"10.1002\/ppul.71156","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fecal elastase-1 in children with cystic fibrosis","volume":"60","author":"Sankararaman","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"2026033102052386000_35.179.250197.102","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40348-024-00178-6","article-title":"Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis \u2013 a real-life insight","volume":"11","author":"Fabricius","year":"2024","journal-title":"Mol Cell Pediatr"},{"key":"2026033102052386000_35.179.250197.103","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/children10020252","article-title":"Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis patients: a cohort study and evaluation of the effect of CFTR modulators","volume":"10","author":"Francalanci","year":"2023","journal-title":"Children"},{"key":"2026033102052386000_35.179.250197.104","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.dld.2014.06.011","article-title":"Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy","volume":"46","author":"Li","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2026033102052386000_35.179.250197.105","doi-asserted-by":"crossref","first-page":"1576602","DOI":"10.3389\/fendo.2025.1576602","article-title":"Non-traditional lipid biomarkers in atherosclerotic cardiovascular disease: pathophysiological mechanisms and strategies to address residual risk","volume":"16","author":"Wang","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026033102052386000_35.179.250197.106","first-page":"100308","article-title":"Coronary artery disease in patients with cystic fibrosis \u2013 a case series and review of the literature","volume":"30","author":"Sandouk","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"key":"2026033102052386000_35.179.250197.107","doi-asserted-by":"crossref","first-page":"00897\u20132024","DOI":"10.1183\/23120541.00897-2024","article-title":"Real-world improvement in ultra-low-dose thoracic computed tomography scores, systemic inflammatory markers and patient-reported outcome measures after elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Ibrahim","year":"2025","journal-title":"ERJ Open Res"},{"key":"2026033102052386000_35.179.250197.108","doi-asserted-by":"crossref","first-page":"17534666251314706","DOI":"10.1177\/17534666251314706","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study","volume":"19","author":"Pepe","year":"2025","journal-title":"Ther Adv Respir Dis"},{"key":"2026033102052386000_35.179.250197.109","unstructured":"Government of Canada . Product information. Date last updated: 14 August 2024. Date last accessed: 31 October 2025. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=100648"},{"key":"2026033102052386000_35.179.250197.110","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jcf.2022.04.010","article-title":"Onset of systemic arterial hypertension after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis: a case series","volume":"21","author":"Gramegna","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.111","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jcf.2024.08.005","article-title":"Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis","volume":"24","author":"Park","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.112","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000193"},{"key":"2026033102052386000_35.179.250197.113","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001303"},{"key":"2026033102052386000_35.179.250197.114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4254\/wjh.v10.i1.34","article-title":"Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease","volume":"10","author":"Ayoub","year":"2018","journal-title":"World J Hepatol"},{"key":"2026033102052386000_35.179.250197.115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jcf.2020.07.022","article-title":"The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients","volume":"19","author":"Havermans","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2026033102052386000_35.179.250197.116","doi-asserted-by":"crossref","first-page":"e0257852","DOI":"10.1371\/journal.pone.0257852","article-title":"COVID-19 pandemic restrictions continuously impact on physical activity in adults with cystic fibrosis","volume":"16","author":"Radtke","year":"2021","journal-title":"PLoS One"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0197-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:06:15Z","timestamp":1774947975000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0197-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":116,"journal-issue":{"issue":"179","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/16000617.0197-2025"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0197-2025","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}